GOSS

SEC filing GOSS Extends Tender to June 2, $181M Notes Tendered, Offers $72M New Debt

6h ago

News Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

14d ago

News Gossamer targets September 2026 seralutinib NDA filing with potential Q3 2027 approval

14d ago

News Wall Street Breakfast: The Week Ahead

14d ago

News Gossamer Bio GAAP EPS of -$0.20 misses by $0.06, revenue of $16.96M beats by $13.14M

15d ago

SEC filing GOSS Reports Q1 2026 Results, FDA Pre‑NDA Meeting, Convertible Notes Exchange Offer

15d ago

SEC filing GOSS Delisted from Nasdaq Global Select Market, $1.00 Bid Price Deficiency, 180-Day Cure Period Until Oct 5 2026

53d ago

News Gossamer Bio downgraded by Cantor on unclear regulatory path for seralutinib

70d ago

SEC filing GOSS Reports $136.9M Cash, $48.9M R&D, Pauses PH-ILD Study, Seeks FDA Meeting

76d ago

News Earnings Preview: Ford’s Trucks, McDonald’s Value, and Ferrari’s Brand Test

112d ago

Scanner Unusual volume (z=5.0)

160d ago

Scanner Unusual volume (z=5.5)

162d ago

Scanner Unusual volume (z=5.5)

163d ago

Scanner Unusual volume (z=5.5)

164d ago

Scanner Unusual volume (z=3.7)

168d ago